Das Fibrodysplasia Ossificans Progressiva (FOP)-Verbindungsregister
FOP-Verbindung: Ein globales Register für die Gemeinschaft von Fibrodysplasia Ossificans Progressiva
The Fibrodysplasia Ossificans Progressiva (FOP) Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. A physician portal (in development) will allow physicians to enter clinical data about their patients. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report data in a shared forum; to improve the collective understanding of FOP natural history; and to advance the understanding of FOP treatment outcomes.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
The FOP Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. No experimental intervention is involved. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report data in a shared forum; to improve the collective understanding of FOP natural history; and to advance the understanding of FOP treatment outcomes.
The Registry collects data through two sources. First, the Patient Portal (launched in July 2015) allows FOP patients and caregivers to enter information about their experiences living with FOP. Second, the Physician Portal (in development) will allow physicians to enter clinical data about patients under their care. The Registry will be capable of including data on specific marketed therapies under the direction and control of a sponsoring pharmaceutical company. Key identifiers will link the physician-reported data with the Patient Portal data.
Participants must have a confirmed diagnosis of FOP and the participant (or a parent or legal guardian) must be willing and able to provide written informed consent. There are no exclusion criteria. Data collected in the Patient Portal include: patient demographics and diagnosis pathway; medical and dental care; clinical research participation and biospecimen donation; heterotopic ossification (bone growth and episodic flare-ups); other signs and symptoms by body system; patient-reported outcomes (physical functioning, pain, fatigue, and general health); and assistive devices, aids, attendants, and adaptations. Because the Registry is designed to accommodate participants along a broad spectrum of FOP disease severity, most of the data fields are optional, allowing participants a high degree of flexibility in how much information they contribute, which also minimizes participant burden.
After completing the informed consent, participants enter their baseline (historical) data. Participants will be encouraged to update their information at least twice per year. Participants may withdraw their consent at any time without prejudice or providing an explanation. The Registry has no pre-specified end date and will continue for as long as it is sustainable and useful to the FOP community.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Sammi Kile, MS
- Telefonnummer: 1-720-341-6999
- E-Mail: registry@ifopa.org
Studieren Sie die Kontaktsicherung
- Name: Mark Hamilton, PhD
- Telefonnummer: 1-203-605-2122
- E-Mail: mark.hamilton@ifopa.org
Studienorte
-
-
Missouri
-
North Kansas City, Missouri, Vereinigte Staaten, 064116
- Rekrutierung
- The International Fibrodysplasia Ossificans Progressiva Association (IFOPA)
-
Kontakt:
- Sammi Kile, MS
- Telefonnummer: 1-720-341-6999
- E-Mail: registry@ifopa.org
-
Kontakt:
- Mark Hamilton, PhD
- Telefonnummer: 1-203-605=2122
- E-Mail: mark.hamilton@ifopa.org
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Individuals with Fibrodysplasia Ossificans Progressive (FOP) from the international FOP community will be invited to join the Registry.
Beschreibung
Inclusion Criteria:
- Participants must have a confirmed diagnosis of FOP.
- Participants (or a parent or legal guardian) must be willing and able to provide written informed consent.
Exclusion Criteria:
- There are no exclusion criteria.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: OTHER
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
FOP Patients
None. IFOPA-REG-001 is a FOP patient observational registry study. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Patient Reported Changes in New Bone Growth Using a Patient-Directed Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The patient is able to report changes in new bone growth among 27 joints and body locations. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Episodic Flare-Ups Using a Patient-Directed Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The patient is able to report changes in episodic flare-ups among 27 joints and body locations. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Mobility Using a Patient-Directed Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The patient is able to report changes in mobility among 27 joints and body locations. |
Baseline, then every six months for up to 10 years
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Patient Reported Changes in Health Resource Utilization Using a Patient-Directed Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The number of visits to a Physician and a Dentist, as well as the number of hospitalizations and reasons for the hospitalizations, are used to assess health resource utilization. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Ear Using a Patient-Directed Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the ears. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Skin Using a Patient-Directed Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the skin. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Central Nervous System Using a Patient-Directed Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the central nervous system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Pulmonary System Using a Patient-Directed Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the pulmonary system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Gastrointestinal System Using a Patient-Directed Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the gastrointestinal system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Cardiovascular System Using a Patient-Directed Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the cardiovascular system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Renal System Using a Patient-Directed Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the renal system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Endocrine System Using a Patient-Directed Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the endocrine system. |
Baseline, then every six months for up to 10 years
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Von Patienten berichtete Veränderungen in den Aktivitäten des täglichen Lebens unter Verwendung des FOP-Fragebogens zur körperlichen Funktionsfähigkeit (PFQ)
Zeitfenster: Baseline, dann alle sechs Monate für bis zu 10 Jahre
|
Baseline, dann alle sechs Monate für bis zu 10 Jahre
|
|
|
Von Patienten gemeldete Veränderungen des allgemeinen Gesundheitszustands unter Verwendung der PROMIS Global Health Scale
Zeitfenster: Baseline, dann alle sechs Monate für bis zu 10 Jahre
|
Baseline, dann alle sechs Monate für bis zu 10 Jahre
|
|
|
Patient Reported Changes in the Need for Assistive Devices, Aids, Attendants, and Adaptations Using a Survey Developed by the IFOPA
Zeitfenster: Baseline, then every six months for up to 10 years
|
The patient is able to respond Yes or No to questions related to his/her need for Assistive Devices, Aids, Attendants, and Adaptations as a result of his/her FOP disease. |
Baseline, then every six months for up to 10 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Mark Hamilton, PhD, International Fibrodysplasia Ossificans Progressiva Association
Publikationen und hilfreiche Links
Nützliche Links
- <p>Click here for more information about this study: The FOP Connection Registry</p>
- <p>The International FOP Association is a 501(c)(3) non-profit organization supporting medical research, education and communication for those afflicted by the rare genetic condition Fibrodysplasia Ossificans Progressiva (FOP).</p>
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- Naturgeschichte
- Mobilität
- Von Patienten berichtete Ergebnisse
- Hallux Valgus
- Patientenregister
- Gemeinsam
- GECK
- Fibrodysplasia ossificans progressiva
- Internationale FOP-Vereinigung
- Patientenvertretung
- Beobachtungsdatenbank
- Knochenmorphogenetisches Protein
- BMP
- Knochenwachstum
- Aufflammen
- Heterotope Ossifikation
- Ektopischer Knochen
- Osteochondrom
- ALK2
- ACVR1
- Aktivin A
- IFOPA
- Activin-A-Rezeptor Typ I
- Aktivin-Rezeptor-ähnliche Kinase-2
Zusätzliche relevante MeSH-Bedingungen
- Knochenerkrankungen
- Erkrankungen des Bewegungsapparates
- Muskelerkrankungen
- Pathologische Prozesse
- Neubildungen
- Neubildungen nach histologischem Typ
- Neubildungen, Binde- und Weichgewebe
- Neubildungen, Knochengewebe
- Neubildungen, Bindegewebe
- Osteochondrodysplasien
- Knochenerkrankungen, Entwicklungs
- Myositis
- Fußdeformitäten
- Pathologische Zustände, Anzeichen und Symptome
- Osteochondrom
- Myositis ossificans
- Hallux Valgus
- Verknöcherung, heterotop
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- IFOPA-REG-001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Formal data sharing agreements are planned between the International FOP Association and biopharmaceutical companies doing research in Fibrodysplasia Ossificans Progressiva (FOP). Publications are also planned with biopharmaceutical companies and physician researchers.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .